MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

HhAntag

CAS No. : 496794-70-8

MCE 站：HhAntag

产品活性：HhAntag 是一种特异性、强效、具有口服活性的 Hh 通路的 SMO 拮抗剂。

研究领域：Stem Cell/Wnt

作用靶点：Smo

In Vitro: HhAntag (2-30 ?M; 72?hours) demonstrates to be?10-times more potent than the natural product SMO antagonist, cyclopamine, at inhibiting Hh pathway activity and it inhibits Hh signalling pathway sensitivitive cells with IC₅₀ values ranging from 2??M to >30??M.
HhAntag inhibits AsPC-1, BXPC-3, CFPAC, HPAC, HPAF-II, KP4, Panc 03.27, PA-TU-8902, PSN-1, SU.86.86 cells with IC₅₀ values of 30 ?M, 5.4 ?M, 5.8 ?M, 2.7 ?M, 6.2 ?M,10.3 ?M, 2.5 ?M, 2.9 ?M, 5.8 ?M and 2.7 ?M, respectively.
HhAntag (100 nM) is needed to completely inhibit Hh signalling in a Hh-responsive human mesenchymal cell line (HEPM) expressing a?GLI?luciferase reporter construct (HEPM-rep), the IC₅₀?of 5?nM 400-times lower than that required to inhibit cell growth by 50% in the most sensitive cancer cell line (1.9?μM).

In Vivo: HhAntag (oral administraion; 75 mg/kg or 100 mg/kg; twice daily; 25 days) results in significant growth delay in HT55 and HT-29 colorectal cell line xenografts models, with average tumour growth inhibitions of 29% and 48%, respectively. Whereas HhAntag had no effect on the growth of DLD-1 xenografts.

相关产品：Bioactive Compound Library Plus  |  Stem Cell Signaling Compound Library  |  Wnt/Hedgehog/Notch Compound Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Cyclopamine  |  SAG  |  Purmorphamine  |  20(S)-Hydroxycholesterol  |  Halcinonide  |  Jervine  |  ALLO-2  |  IHR-Cy3

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。